Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 6, 2011, Pages 1392-1395

  Eagye, Kathryn J ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

Antimicrobial resistance; Gram negative; Pseudomonas aeruginosa

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ANTIPSEUDOMONAL CARBAPENEM; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; DORIPENEM; ERTAPENEM; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; TOBRAMYCIN; UNCLASSIFIED DRUG;

ADOPTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS RESISTANCE; DRUG USE; DRUG UTILIZATION; HOSPITAL; HUMAN; MULTICENTER STUDY; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMS; CARBAPENEMS; DRUG UTILIZATION; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 79956044932     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr141     Document Type: Article

References (10)

1. Livermore DM, Carter MW, Bagel S et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 2001; 45: 1860-7.
2. Livermore DM, Mushtaq S, Warner M. Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. J Antimicrob Chemother 2005; 55: 306-11.
3. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004; 48: 3086-92.
4. Goff DA, Mangino JE. Ertapenem: no effect on aerobic Gram-negative susceptibilities to imipenem. J Infect 2008; 57: 123-7.
5. Goldstein EJ, Citron DM, Peraino V et al. Introduction of ertapenem into a hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53: 5122-6.
6. Jones RN. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin Respir Crit Care Med 2003; 24: 121-34.
7. Lima AL, Oliveira PR, Paula AP et al. The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study. Infect Control Hosp Epidemiol 2009; 30: 487-90.
8. Eagye KJ, Nicolau DP. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals. Infect Control Hosp Epidemiol 2010; 31: 485-90.
9. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32: 470-85.
10. Rosenthal VD, Maki DG, Mehta A et al. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control 2008; 36: 627-37.